ESR1 and breast cancer: Using 16α-[18F]fluoro-17β-estradiol (FES) PET compared to [18F]FDG PET, Boers et al. found a heterogeneous [18F]FES binding in 20 of 30 patients with metastasized BC [32], which indicates a possible synchronous ER heterogeneity in advanced BC patients.